Syntara Limited · ASX:SNT
Syntara — Non-Deal Roadshow (April 2024)
20 slides from Syntara's roadshow presentation, Apr 30, 2024
Slide 1: Non Deal Roadshow
For personal use only ™ Non Deal Roadshow Gary Phillips, CEO April/May 2024
Slide 2: Forward looking statement
Forward looking statement For personal use only This document contains involve known and unknown forward-looking statements, risks, uncertainties and other including statements factors, many of which are concerning Syntara’s future beyond our control, and which financial position, plans, and may cau
Slide 3: Global leaders in lysyl oxidase enzymes; Prioritising Myelofibrosis
For personal use only Global leaders in lysyl oxidase Prioritising Myelofibrosis (MF) • Market opportunities in excess of US$1b per enzymes with three Nature annum and recent history of biotech exits in publications and a pipeline of clinical excess of US$1.7b stage drugs in fibrosis and • SNT-5505
Slide 4: Shareholders & cash
Shareholders & cash Financial Information (ASX: SNT) 28 April 24 Share Price & Volume For personal use only Share price $0.017 0.07 Market Cap A$20m 0.06 Cash balance (31 March 2024)1 A$7m 0.05 Enterprise value A$13m Note: 0.04 1. Additional funds expected from acquiror of MBU (~$6m) and returned se
Slide 5: Syntara Board under new leadership and downsized
Syntara Board under new leadership and downsized Significant international pharmaceutical experience For personal use only Dr Kathleen Metters Dr Simon Green Gary Phillips Hashan De Silva Chair Non-Executive Director Chief Executive Officer Non-Executive Director • Former Senior Vice President • Exp
Slide 6: Syntara is the global leader in lysyl oxidase chemistry and biology
Syntara is the global leader in lysyl oxidase chemistry and biology Multi year research program leveraged with extensive For personal use only scientific collaborations worldwide has delivered 3 drugs now in phase 1c/2 studies Lysyl oxidases mediate the final stage in fibrosis SNT-5505 in Oncology T
Slide 7: Preclinical science and collaborations validated in high impact publications
Preclinical science and collaborations validated in high impact publications For personal use only Myelofibrosis Myelodysplastic • Treatment with Syndrome lysyl oxidase • In xenograft inhibitor mouse model that significantly closely resembles reduced reticulin human disease, fibrosis and SNT-5505 on
Slide 8: Myelofibrosis (MF)
For personal use only Myelofibrosis (MF)
Slide 9: Myelofibrosis
Myelofibrosis A rare type of bone marrow cancer that disrupts the body's normal production of blood cells For personal use only Key Facts Primary Myelofibrosis is Current standard SNT-5505 characterised by a build up of scar of care (SoC): JAK inhibition In contrast to SoC tissue (fibrosis) in bone
Slide 10: SNT-5505 Phase 2a trial (INTERIM results)
SNT-5505 Phase 2a trial (INTERIM results) Demonstrates improvements in fibrosis grade, excellent safety profile and promising signs of clinical activity For personal use only Study status Efficacy • 100% of target (24 pts) enrolled • 5/ 10 evaluable patients* had improved bone • 11 patients having c
Slide 11: Phase 2a study; SNT-5505 in patients on a stable dose of JAK inhibitor
Phase 2a study; SNT-5505 in patients on a stable dose of JAK inhibitor Study Plan For personal use only Fastest route to meaningful data with no dose escalation and utilizing existing trial infrastructure • 19 clinical trial sites • Recruitment Study Treatment started 13 Dec Design Endpoints Populat
Slide 12: Myelodysplastic Syndromes (MDS)
For personal use only Myelodysplastic Syndromes (MDS)
Slide 13: Myelodysplastic syndrome (MDS) is a blood cancer
Myelodysplastic syndrome (MDS) is a blood cancer Diverse bone marrow disorders characterized by inadequate production of healthy blood cells Key Facts 12–20k new cases are reported every Treatment of MDS For personal use only year in the US (87k p.a. worldwide) Current standard of care Drugs in deve
Slide 14: Phase 1c/2a study; SNT-5505 in MDS patients
Phase 1c/2a study; SNT-5505 in MDS patients Grant funded investigator study backed by ALLG with initial results due mid 2025 Study organisation For personal use only • $0.83m grant from the Australian Medical Research Future Study Treatment Fund (MRFF). Patients Design Endpoints Population Cohort •
Slide 15: Skin Scarring
For personal use only Skin Scarring
Slide 16: Hypertrophic and keloid scarring
Hypertrophic and keloid scarring Cutaneous scarring following skin trauma or a wound is a major cause of morbidity and disfigurement For personal use only Key Facts • Mechanisms underlying scar • Pre clinical evidence formation are not well established; prophylactic and - Treatment with SNT-6302 100
Slide 17: SNT-6302 Phase 1c Trial in established skin scars (Solaria)
SNT-6302 Phase 1c Trial in established skin scars (Solaria 2); Top line results For personal use only SNT-6302 well tolerated Mean inhibition of LOX Meaningful changes in the Longer study required to and demonstrated a activity 66% compared to composition of the scars show appearance and good safety
Slide 18: Potential to deliver near term value
Potential to deliver near term value Pipeline creates multiple opportunities in high value markets For personal use only Addressable market Drug Candidate Indication Phase Upcoming Milestones (US$) Interim 6 month data Myelofibrosis (MF) Phase 2 ~$1 billion1 Q4 2024 SNT-5505 Myelodysplastic Syndrome
Slide 19: Recent & upcoming news flow
Recent & upcoming news flow Strong and growing pipeline with advancement in studies expected to provide value inflection points For personal use only COMPLETED COMPLETED COMPLETED Q2 2024 Mid 2024 Q4 2023 Q4 2023 Q4 2023 SNT-4728 iRBD / SNT-5505 phase 2a SNT-5505 phase 2a Pan-LOX scar SNT-5505 phase
Slide 20: Contact
For personal use only Gary Phillips Syntara Limited ABN 75 082 811 630 Chief Executive Officer gary.phillips@syntaraTX.com.au David McGarvey Chief Financial Officer david.mcgarvey@syntaraTX.com.au www.syntaraTX.com.au